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Introduction: Scrapie infection instigates the in viva 
conversion of normal, protease-sensitive prion protein 
(PrPc) into a protease-resistant form (PrPsc) by an 
unknown mechanism. In vitro studies have indicated that 
PrPSC can induce this conversion, consistent with pro- 
posals that PrPSC itself might be the infectious scrapie 
agent. Using this cell-free model of the PrPC to PrPSC 
conversion, we have studied the dependence of conver- 
sion on reactant concentration, and the properties of the 
PrPsc-derived species that has converting activity. 
Results: The cell-free conversion of 35S PrPC to the 
proteinase K-resistant form was dependent on the 
reaction time and initial concentrations of PrPSc (above 
an apparent minimum threshold concentration) and 
35S PrPC. Analysis of the physical size of the converting 
activity indicated that detectable converting activity was 
associated only with aggregates. Under mildly 
chaotropic conditions, which partially disaggregated 
PrPSC and enhanced the converting activity, the active 
species were heterogeneous in size, but larger than either 
effectively solubilized PrP or molecular weight standards 
of -2000 kDa. 
Conclusions: The entity responsible for the converting 
activity was many times larger than a soluble PrP 
monomer and required a threshold concentration of 
PrPSC. These results are consistent with a nucleated 
polymerization mechanism of PrPSC formation and 
inconsistent with a heterodimer mechanism. 
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Introduction 
The transmissible spongiform encephalopathies (TSEs or 
prion diseases) include Creutzfeldt-Jakob disease, Gerst- 
mann-Straussler disease and kuru in humans, scrapie in 
sheep, mice and hamsters, and bovine spongiform 
encephalopathy (for review see [l]).These neurodegenera- 
tive diseases are characterized by the accumulation of 
abnormal protease-resistant forms of the prion protein 
(PrP) , for example PrP sc, in diseased animals. PrPsc forms 
insoluble aggregates (e.g., amyloid plaques) and is partially 
resistant to proteinase K (PK) [2-41, which removes only 
-67 amino acid residues (6-7 kDa) from the amino termi- 
nus of each residual molecule in the aggregates [5,6]. In 
contrast, the normal, non-pathogenic form, PrPc, is 
soluble in mild detergents and fully degraded by PK [7,8]. 
PrPc has been shown to be the precursor of PrPsc [9,10]. 
No covalent difference has been detected between PrPc 
and PrPsc that explains their differences in aggregation 
properties and protease sensitivity [6,11]. 
Although infectivity has not been separated from PrPsc 
[12,13], the exact makeup of the infectious agent remains 
speculative. One school of thought initiated by Griffith in 
1967 [14] postulates that the agent is a pathogenic form of 
a host protein which, upon entering a new host, can 
induce the conversion of a normal endogenous protein to 
more of the pathogenic form [14-16].The inability to sep- 
arate PrPSC and scrapie infectivity has made PrPsc the 
prime candidate for this putative infectious protein agent 
[12,13,16]. Supporting this model are observations that 
PrPc will convert to PK-resistant forms when incubated 
with preexisting PrPsc in a cell-free system (Fig. 1) 
[17-191. It is not yet known whether new scrapie infec- 
tivity is generated upon conversion of PrPc to these 
PK-resistant forms. Further biochemical studies with this 
cell-free system have shown, however, that there is scrapie- 
strain and PrP-species specificity in the PrPc-PrPsc inter- 
actions that could account for the observed differences 
between scrapie strains and the barriers to interspecies 
transmission of scrapie, respectively [18,19]. The precise 
nature and mechanism of the activity within PrPsc prepa- 
rations that converts PrPc to protease-resistant PrP is not 
well defined. 
Any mechanistic model for PrPsc formation must address 
two questions regarding the conversion reaction. First, what 
catalyzes the conversion of PrPc to PrPsc (the ‘converting 
activity’)? Two distinct models have been proposed for how 
this occurs. According to the heterodimer/unfolding 
model, the catalyst (PrPsc) is a monomeric conformational 
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Fig. 1. A possible analogy between the in vitro conversion of 
PrPC to PrPsc-like, PK-resistant forms, and scrapie infection in 
vivo. The in vitro system mimics in vivo infection in that pro- 
tease-resistant PrP is produced by a mechanism that exhibits 
host-species and scrapie-strain specificities, but the generation of 
new scrapie infectivity remains to be demonstrated. 
isomer of PrP that catalyzes the conformational change via 
a PrPc-PrPsc heterodimer [14-l 61. Alternatively, the 
nucleation model holds that the catalyst is an ordered 
multimeric aggregate of PrP (PrPsc) which acts as a seed 
for polymerization of PrP [20,21]. Second, what is the 
barrier that prevents the spontaneous conversion of PrPc 
to PrPsc? The heterodimer/unfolding model holds that the 
barrier is the activation energy for the conformational 
change in PrP c In the nucleation model, the barrier is the . 
unfavorable formation of a multimeric nucleus.TSE infec- 
tion would then bypass nucleus formation by providing 
preformed PrPsc seeds. 
Attempts to determine the mechanism of PrPSC forma- 
tion are complicated by the fact that the reaction itself 
and the physical state of PrPSC are difficult to monitor in 
vivo.The in vitro system described above does, however, 
allow direct characterization of the species capable of 
inducing the conversion of PrPC to PrPsc-like protease- 
resistant forms. Here we describe experiments assessing 
the dependence of the conversion reaction on the con- 
centration of the reactants and the determination of the 
size of the molecular species associated with converting 
activity by sedimentation and ultrafiltration analysis. 
Results 
Concentration dependence of the cell-free conversion of 
3% PrPc to the protease-resistant form 
The extent of conversion of 35S PrPC to protease-resis- 
tant, PrPsc-like species was followed as a function of time 
and the amount of PrPsc added to the reaction mixture 
(Fig. 2a, b). In this reaction, 35S PrPc immunoprecip- 
itated from uninfected fibroblast cells was mixed with 
scrapie-brain-derived PrPSC in 2.5 M guanidine-HCl 
(GdnHCl) and then diluted to 0.75 M GdnHCl to initi- 
ate the conversion reaction. After the incubation period, 
the products of the reaction were treated with PK to test 
for the conversion of 35S PrPC to PK-resistant forms. For 
quantitative comparisons throughout this study, ‘con- 
version’ was defined as the formation of 16-20 kDa 
PK-resistant 35S PrP, since this is the size expected for 
PK-digested PrP sc derived from this type of PrPC pre- 
cursor [17,22] (6-7 kDa lower in molecular weight than 
the full length 23-27 kDa precursor; see also Fig. 4a). 
Figure 2b illustrates the increase in conversion as either 
the initial concentration of PrPSc or the incubation 
period were increased. 
The extent of conversion at 22 h was then determined 
over a wider range of PrPsc concentrations (Fig. 2~). 
Increasing the concentration of PrPsc always increased 
the extent of conversion, although at high concentrations 
of PrP ( sc 2 100 pg ml-l) the concentration dependence 
was less marked. At concentrations of PrPsc from 8 to 
62 pg ml-l, a plot of percent conversion versus initial 
concentration of PrPsc was essentially linear (Fig. 2d). 
Extrapolation of such a plot to percent conversion = 0 
resulted in a non-zero x-intercept (-5.1 pg ml-’ or 
150 nM), providing evidence that a threshold concentra- 
tion of PrPSC was required for the existence of convert- 
ing activity (see below). Further, conversion attempted 
with 2 or 4 pg ml-’ PrPSC gave no detectable conversion 
product (data not shown). The observed threshold con- 
centration probably depends upon the presence of 
GdnHCl and thus may be different (presumably lower) 
in the absence of GdnHClThe dependence of the total 
conversion at 22 h on the concentration of 35S PrPC was 
also determined (Fig. 2e).At a constant concentration of 
PrPSc (125 kg ml-‘), the formation of 35S-labeled con- 
version product was directly dependent on the initial 
concentration of 35S PrPC. Extrapolation to 0 % conver- 
sion demonstrated no threshold PrPC concentration. 
Note, however, that, ,due to the limited availability of 
PrPc, the range of concentrations of 35S PrPC examined 
was -1% of the range of PrPSC concentrations tested in 
Fig. 2b (see Materials and methods). 
Sedimentation properties of the converting activity 
We have reported that pretreatment of PrPSC with 
3M GdnHCl enhances the converting activity [17]. 
Subsequently, we have found that the optimal pretreat- 
ment concentration varies from 2 to 3M GdnHCl 
depending upon the particular PrPsc preparation (data 
not shown). Such GdnHCl treatments are also known 
to partially disaggregate PrPSC [23,24]. To determine 
whether converting activity was associated with a solubil- 
ized PrPsc fraction or a residual PrPSC aggregate, we ana- 
lyzed the sedimentation properties of the converting 
activity in the presence of GdnHCl. Treatments with 
GdnHCl can alter the biochemical properties (i.e. PK 
resistance and tendency to aggregate) of PrPSC that are 
usually used to define PrPSC and distinguish it from PrPc. 
Nonetheless, to define the origin of samples derived from 
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Fig. 2. The conversion reaction is dependent on the time of incubation and the concentrations of PrPSC and 35S PrPC. (a) Converting 
activity. PK-resistant 35S PrP species generated from the incubation of 35S PrPC with different concentrations of PrPsC (pg ml-‘) for 
various lengths of time (h) as described for the conversion reaction in Materials and methods. The PrPC used in this study lacks a GPI 
anchor and is predominantly unglycosylated (23 kDa), with a minority monoglycosylated (27 kDa) species (see Fig. 4a, for example). 
The bracket on the left and in subsequent figures indicates the PrPsc-like 16-20 kDa bands that were used in the quantitative compar- 
isons described below. All lanes represent reactions initiated with 60 000 cpm of 35S PrPC. Molecular weight markers are indicated at 
the right in kDa. (b) Percent of 35S PrPC converted to 16-20 kDa PK-resistant species (mean +/- standard deviation of triplicate determi- 
nations) after incubation with designated PrPSC concentrations as a function of incubation time (includes data shown in (a)). Only 
bracketed bands as shown in (a) were counted as converted product using the Phosphorimager. Cl, 125 kg ml-‘; 0, 62 pg ml-‘; 
??, 31 pg ml-1 (c) Percent conversion in 22 h versus PrPsC concentration. (d) Expanded plot of linear region of data in panel (c) showing 
a line fit by simple linear regression with an x-intercept of 5.1 pg ml-’ (150 nM PrP SC, based on a molecular weight of 35 kDa). (e) Plot 
of the total 16-20 kDa conversion product versus the initial concentration of 35S PrPC. Semi-quantitative immunoblotting was used to 
estimate the total PrPC as 10 ng per 60 000 cpm. The concentration of PrPSC and incubation time were constant in these reactions at 
125 bg ml-’ and 22 h, respectively. The percentage of the initial 35S PrPc that was converted was -20% over the entire range tested. 
PrPsc preparations, we will continue to refer to them as original PrPsc preparation and increased the overall con- 
PrPSC, realizing that the PrP in these samples might no verting activity [17], only sedimentable aggregates had 
longer have the properties originally used to define PrPsc. converting activity. 
PrPsc pretreated with 3 M GdnHCl was centrifuged under 
conditions predicted to pellet 90% of particles that have a 
sedimentation coefficient at 20°C in water, sZow= 12 
(based on calculations described in Materials and ‘meth- 
ads). The pellet and supernatant &actions were tested for 
converting activity (Fig. 3a) and analyzed for PrP content 
(without PK treatment) by immunoblotting (Fig. 3b). The 
vast excess of PrPsc over PrPc in the reaction dictates that 
the PrP detected by immunoblot was derived predom- 
inantly from PrPsc. A majority of the PrP was found in the 
supernatant, but converting activity was found only in the 
pellet. This indicated that, although the 3M GdnHCl 
treatment effectively solubilized more than half of the 
To further compare the sedimentation rates of the entity 
responsible for converting activity and of GdnHCl- 
solubilized PrPsc, a series of sedimentation velocity cen- 
trifugations was performed (Fig. 4). In this experiment, 
PrPsc pretreated in 2.5 M GdnHCl was used because pre- 
liminary experiments with this particular PrPsc prepara- 
tion indicated that the converting activity was optimal 
with this pretreatment (see below) .The sample was placed 
over a layer of 5% sucrose in 2.5 M GdnHCl and cen- 
trifkged at various speeds. Fractions of the gradient were 
tested for converting activity (Fig. 4a, d) and analyzed by 
immunoblotting for total PrP content (Fig. 4b). With spins 
of 2000 and 8000 g, a majority of the converting activity 
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Fig. 3. The converting activity can be pelleted. (a) Converting 
activity (as described in legend to Fig. 2a) in aliquots of unsepa- 
rated (total) PrPSC in 3 M GdnHCl or of pellet or supernatant (Sup) 
fractions of the same after centrifugation at 217 OOOg max. 
(b) tmmunoblot showing relative total PrP content of the same 
fractions used in the conversion reaction in (a). A polyclonal 
rabbit antiserum raised against a synthetic peptide corresponding 
to hamster PrP residues 90-l 04 was used [471. Molecular weight 
markers are indicated at the right in kDa. 
remained in the top (T) fraction corresponding to the 
sample zone (Fig. 4a, d). A spin at 70000 g cleared > 95% 
of converting activity from the sample zone (T). 
Calculations based on the clearing factor (k) for this rotor 
speed and sample zone radius estimated that 90 % of parti- 
cles of szO w = 17 would be cleared from the sample zone 
under these conditions. A 2340008 spin cleared all 
detectable converting activity from both the sample zone 
and middle (M) fractions. At this speed, L 90% of particles 
ofs 20 w 2 5 would be cleared from the sample zone. In 
contrast to the converting activity, at least half of the PrP 
detected by immunoblot remained in the top (sample) 
zone after these spins (Fig. 4b). This confirmed that the 
detectable converting activity was associated with sedi- 
mentable aggregates rather than with the non-sedimenting 
PrPsc generated by the GdnHCl treatment. 
A set of single-subunit molecular weight standard pro- 
teins (lactalbumin (14 kDa), trypsin inhibitor (20 kDa), 
carbonic anhydrase (30 kDa), ovalbumin (43 kDa), bovine 
serum albumin (67 kDa), and phosphorylase b (94 kDa); 
data not shown) and thyroglobulin (669kDa, with 
335 kDa subunits; Figure 4c) were centrifuged at 70 000 
and 234 OOOg in identical gradients containing 2.5 M 
GdnHCl, but none sedimented through the gradient to 
the extent observed for the converting activity at those 
centrifugal forces. Native thyroglobulin is 19S, but the 
effect of 2.5 M GdnHCl on the sedimentation properties 
of thyroglobulin and the other protein molecular weight 
standards is not known. The sedimentation behavior of 
blue dextran (2000 kDa) was closest to that of the con- 
verting activity, but the clearance of the blue dextran 
absorbance from the sample (T) zone was still slower 
than that of the converting activity (Fig 4a, c, d). Thus, 
the detectable converting activity sedimented faster than 
the solubilized PrP (monomeric MW = 25-36 kDa), 
other proteins up to 335 kDa (if thyroglobulin subunits 
are dissociated in 2.5M GdnHCl) and the 2000-kDa 
blue dextran. 
To address the possibility that solubilization of convert- 
ing activity might be achieved at a different GdnHCl 
concentration, PrPSC was treated in 0, 1.5, 2.0, 2.5 and 
3.0 M GdnHCl and centrifuged at 234 000 g in gradients 
formed with a matching concentration of GdnHCl. In 
all cases, the detectable converting activity was cleared 
completely from the sample zone and sedimented to the 
bottom (B) and pellet (P) fractions (data not shown), 
indicating that the converting activity was associated 
with aggregates regardless of the GdnHCl concentration. 
GdnHCl concentrations greater than 3M were not 
tested because, as noted above, converting activity is 
unstable at concentrations 2 3.5M and not renaturable 
by subsequent dilution of the GdnHCl. 
Sedimentation of PK-treated converting activity and PrPSC 
Our treatment of PrPSC with PK results in the loss of 
approximately half of the total PrP and removal of 67 
amino-terminal amino acids (6-7 kDa) from the remain- 
ing PrPSC to generate a predominantly 27-30 kDa 
protein (PrP27-30) (Fig. 5; [5,6]). In addition, PK treat- 
ment degrades much of the large molecular weight 
(> 40 kDa) material that is observed by SDS-PAGE with 
typical PrPSC preparations (PrP27-30 is > 90% pure as 
determined by SDS-PAGE [25]). Since PK treatment 
does not eliminate the converting activity associated 
with PrPSC [19], we tested whether PK pretreatment 
would allow the converting activity to be more readily 
disaggregated by GdnHCl. PrP27-30 was treated with 
2.5M GdnHCl and subjected to a 234000g gradient 
centrifugation identical to that performed with the 
untreated PrPsc preparation. Analysis of the converting 
activity in the gradient fractions indicated that it pelleted 
(Fig. 6a) as it did prior to PK digestion (Figs. 3 and 4). 
Analysis of the total PrP by immunoblot indicated that, 
in contrast to the situation with the untreated PrPSC, 
none of the PrP27-30 was effectively solubilized by the 
GdnHCl (Fig. 6b). This result suggested that PK diges- 
tion of PrPSC removed the PrP species that could be 
effectively solubilized from the PrPSC aggregates; it is the 
aggregates of PrP sc that are associated with converting 
activity in the presence of 2.5 M GdnHCl. 
Ultrafiltration of converting activity in CdnHCl 
As another test of the size of molecular species associated 
with converting activity, ultrafiltration was performed on 
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Fig. 4. Converting activity sediments 
more rapidly than both the majority of 
PrPsc protein and molecular weight stan- 
dards up to 20OOkDa. (a) Converting 
activity (as described in legend to Fig. 2a) 
in aliquots of unfractionated (total) PrPSC 
in 2.5 M GdnHCl or top (T), middle (M), 
bottom (B), and pellet (P) fractions (as 
indicated by diagram at left) after cen- 
trifugation at the designated g force. One 
third of the 35S PrPC used in each conver- 
sion reaction is shown without PK diges- 
tion in the PrPc lane. Molecular weight 
markers are indicated at the right in kDa. 
(b) lmmunoblot of the total PrP in frac- 
tions described in (a). (c) Sedimentation 
of thyroglobulin (669 kDa total, 335 kDa 
subunits; clear bars) or blue dextran 
(2000kDa; hatched bars) in 2.5 M 
GdnHCl on identical gradients. The data 
points show the percent of the amount 
loaded (mean +/- SD.) in fractions from 
three gradients. (d) Clearance of the con- 
verting activity from the sample (T) zone 
after centrifugation at the designated rel- 
ative centrifugal forces (RCF). The ordi- 
nate is the percent reduction in the 
conversion activity generated by aliquots 
of the T fractions as compared to the total 
unfractionated PrPSC sample. The data 
points show the mean +/- range of mea- 
surements from two independent experi- 
ments (including the one in (a)), except 
in the case of the 2000g spin which is 
from a single determination. For compa- 
rison, the calculated szc w values of parti- 
cles that would be 90% cleared from the 
sample zone under the conditions of 
each centrifugation are shown. 
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PrPsc (not treated with PK) in 3M GdnHCl. PrPSc- 
derived PrP was retained by a filter with a nominal mol- 
ecular weight limit (NMWL) rating of 100kDa (data not 
shown) but passed through a 300 kDa NMWL filter 
(Fig. 7b). In contrast, the converting activity was retained 
by the 300 kDa NMWL filter (Fig. 7a). Thus, the 
300 kDa NMWL filter separated the converting activity 
from the bulk of the solubilized PrPSC, providing addi- 
tional evidence that the converting activity is associated 
only with aggregates larger than the dissociated PrP 
Since the maximum pore size of the 300 kDa NMWL 
filter is estimated by the manufacturer to be -30 nm, the 
Stokes radius of the inactive PrP that passed through this 
filter would then be < 30 nm.The Stokes radius of the 
converting activity must be larger than that of the PrPSC- 
derived material without converting activity; however, 
one cannot definitively conclude that it is greater than 
30nm because of possible polarization layer effects and 
the likelihood that the average pore size of the filter is 
much lower than 30 nm. 
Similar filtration experiments performed with filters with 
nominal maximum pore sizes of lOO-450nm indicated 
that converting activity could pass through the filters 
(data not shown). The passage of converting activity 
through the 100 nm (maximum pore size) filter indicated 
that under these conditions it can have a Stokes radius 
of I 100 nm. 
Ultrafiltration of PK-treated converting activity in GdnHCl 
Ultrafiltration of PK-treated PrPsc in 3 M GdnHCl indi- 
cated that the converting activity was retained by both 100 
and 300 kDa NMWL filters (Fig. 8a) as was the case with 
the untreated PrPsc (Fig. 7a). In contrast to the untreated 
PrPSC, little (~15%) of the PK-treated PrPsc passed 
through the 300 kDa NMWL filter (Fig. 8b). This was 
consistent with the sedimentation analysis of PK-treated 
PrPsc (Fig. 6b), which also indicated reduced solubilization 
by GdnHCl compared to the PrPsc that was not treated 
with PK. 
Discussion 
Association of converting activity with PrPSC aggregates 
The recently developed cell-free reaction for converting 
PrPc to PK-resistant forms has made it possible to begin 
to characterize the components and mechanism of the 
converting activity under defined conditions. The depen- 
dence of the conversion rate on the amount of PrPSC in 
the reaction mixture establishes that a component of the 
PrPsc preparation is involved in the rate-determining 
step. The sedimentation and filtration of the converting 
activity indicates that it is associated with aggregates that 
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Fig. 5. SDS-PAGE with silver staining of PrPSC before and after treat 
ment with PK as described in Materials and methods. The thin band 
seen just above 30 kDa in the third lane was probably PK itself. A 
115 dilution of the starting material is shown for comparison. 
Molecular weight markers are indicated at the left in kDa. 
range in size from being at least several times larger than 
solubilized PrP to macroscopic particles. The sedimenta- 
tion and filtration data provide complementary informa- 
tion about the sizes of species with converting activity. 
The sedimentation rate of a particle is a function of both 
its size and shape. Thus, one might argue that subtle 
differences in sedimentation of PrP species could be 
explained by differences in conformation rather than 
aggregation state and that converting activity is associated 
with a more compact, rapidly sedimenting conformer. If 
this were the case, however, the more compact con- 
former would also be expected to pass more readily 
through the pores of an ultrafiltration membrane than a 
more extended conformer with a larger Stoke’s radius. 
The opposite result was observed, which is consistent 
only with the converting activity being associated with 
an aggregate of larger mass than the solubilized PrPThis 
conclusion was confirmed by the observation that the 
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Fig. 6. Both the converting activity and all of the remaining PrPSC 
sediment after PK treatment. PrPSC was treated with PK as des- 
cribed in Materials and methods, incubated at 1 mg ml-’ for 5 h 
at 37°C in 3 M GdnHCl and fractionated at 234000g max on a 
gradient identical to those described in Figure 4. (a) Converting 
activity (as described in the legend to Fig. 2a) in unfractionated 
(total) PK-treated PrPSC in 2.5 M GdnHCl or top (T), middle (M), 
bottom (B), and pellet (P) fractions. One third of the 35S PrPC used 
in each conversion reaction is shown without PK digestion in the 
PrPC lane. (b) lmmunoblot of the total PrP in the fractions 
described in (a). Molecular weight markers are indicated at the 
right in kDa. 
detectable converting activity sediments faster than other 
molecules up to 50 times greater in molecular weight than 
monomeric PrP 
The nature and origin of the PrP without converting 
activity that was solubilized from the original PrPSC 
aggregate with GdnHCl is not clear, but GdnHCl- 
soluble subfractions of PrPsc have also been observed by 
other investigators [23,24]. Since these PrP molecules 
appear to be more sensitive to PK than the residual 
PrP 27-30 aggregate (see Fig. 6), they may be PrPC 
molecules that are bound (normally or artifactually) to 
PrPsc without being fully integrated and converted to 
the PK-resistant state characterized by PrP 27-30. The 
stimulation of converting activity by the GdnHCl treat- 
ments of PrPSC [17] may be due to the removal of these 
PrP molecules which may block access to active catalytic 
surfaces for the conversion reaction. The presence of 
these GdnHCl-soluble PrP molecules might also con- 
tribute substantially to the PrPc precursor concentration 
once the GdnHCl is diluted for the conversion reaction. 
Ramifications regarding models of PrPSC formation 
Evidence of the sizes of species with converting activity 
is useful in discriminating between various theories for 
the mechanism of PrPSC formation. The observation 
that a wide range of PrP aggregates possess converting 
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Fig. 7. Ultrafiltration separates solubilized PrPSC from conver- 
ting activity. PrPSC in 3 M GdnHCl was filtered through a 
300kDa NMWL filter as described in Materials and methods. 
(a) Converting activity in equivalent aliquots of the retentate, fil- 
trate and unfractionated sample (total). (b) lmmunoblot of the total 
PrP in same fractions. Molecular weight markers are indicated at 
the right in kDa. 
activity is consistent with the nucleation model. As in 
the case of amyloid formation, any aggregate larger 
than the critical nucleus would be a competent seed for 
polymerization [21]. 
The observation of a threshold concentration for con- 
verting activity is also consistent with the nucleation pro- 
posal, in which the converting activity is a seed for the 
ordered aggregation of PrP The threshold concentration 
may correspond to the critical concentration which is 
observed for protein polymerization processes known to 
occur via a nucleation-dependent mechanism (e.g., 
microtubule formation, flagellum formation, sickle cell 
fibril formation) [26-291. Below the critical concentra- 
tion, the predominant -species is the monomer. The 
nucleus is, by definition, the highest-energy species along 
the polymerization pathway and the smallest possible seed 
for polymerization [21]. Since the nucleus is almost com- 
pletely dissociated below the critical concentration, one 
would not expect to see conversion. Our attempts to 
observe conversion below the reported threshold concen- 
tration were unsuccessful. Above the critical concentra- 
tion, the predominant species are large aggregates, in 
equilibrium with the monomer. All of these post-nucleus 
-30 
Fig. 8. The PrPsc and converting activity remaining after PK treat- 
ment is retained upon ultrafiltration. The PK-treated PrPsC 
described in Figure 6 was incubated in 3 M CdnHCl at a concen- 
tration of 1 mg ml-’ and filtered as described in Figure 7 except 
that 100 kDa NMWL filters were also used. (a) Converting activ- 
ity in equivalent aliquots of the indicated fractions. One third of 
the 35S PrPC used in each conversion reaction is shown without 
PK digestion in the PrPC lane. (b) lmmunoblot of the total PrP in 
the same fractions. Molecular weight markers are indicated at 
the right in kDa. 
aggregates are, in theory, able to seed polymerization. The 
non-first-order concentration dependence seen at high 
concentrations of PrPsc may be due to ultrastructural 
effects, for example, fibril bundling, which may occur in 
those concentration ranges. Bundling could decrease the 
specific activity of the seed by blocking the active 
growth faces [21]. The threshold concentration observed 
(-150 nM) may reflect the very low solubility of PrPSC 
under the conditions of the in vitro conversion reaction 
(0.75M GdnHCl).The solubility of PrPsc might be much 
lower under more physiological conditions, allowing for 
further dilution of PrPsc before activity is lost. 
Although PrPsc IS usually isolated in rapidly sedimenting 
aggregates, it has been suggested that the aggregation of 
PrPsc may be largely an artifact of purification and that the 
active species is a PrPSC monomer (heterodimer model) 
that dissociates as a discrete unit from the aggregate [16]. 
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The cell-free conversion assay has given us the opportunity 
to test directly for converting activity in subfractions of 
PrPsc preparations treated with a wide range of conditions 
(from 0 to 3M GdnHCl) with varying tendencies to solu- 
bilize PrP from the preexisting PrPsc aggregate. In all cases, 
converting activity was detected only in the aggregate fiat- 
tions, and not in supernatants or filtrates containing dissoci- 
ated PrPsc. These data are inconsistent with the idea that 
the active PrPsc species is solely a monomer or small 
oligomer. Finally, the threshold concentration effect would 
not be expected of a monomeric species. 
It is instructive to consider separately a heterotrimer 
model, which postulates that the converting activity is a 
PrPSC dimer. The concentration-dependence of dimer 
formation would be second-order, not first-order as 
observed. In addition, a dissociating dimer could pass 
through the filter in monomeric form and reassociate in 
the filtrate. A nondissociating dimer, analogous to the 
dimeric form of CD2 that has recently been character- 
ized [30], would show a first-order concentration depen- 
dence, but not a threshold concentration. A dimer with 
an extremely high association equilibrium constant could 
produce a curve resembling the one seen in Figure 2d; 
however, it is clear from the sedimentation experiments 
that a PrPsc dimer is not the major converting species. 
It is theoretically possible that the PrPsc-derived convert- 
ing activity could be attached to a non-PrP molecule(s) 
or aggregate of much greater size, accounting for its sedi- 
mentation and filtration properties. Although the com- 
plete composition of these aggregates is not clear, silver 
stain and immunoblotting analyses of fractions contain- 
ing converting activity indicate that PrPSC is the predom- 
inant protein component, especially after PK digestion 
(Fig. 5) [25]. Therefore, the particulate behavior of the 
converting activity is probably due to PrPSC aggregates, 
not to PrPSC monomers bound to a much larger mass of 
other molecules. This does not eliminate the possibility 
that some non-PrP molecules have gone undetected or 
could be minor constituents of the aggregates. This is 
especially plausible because of the vast excess of PrPSC 
over 35S PrPc in the present conversion reaction. For 
instance, glycosaminoglycans and other possible ligands 
may be important in the formation or stabilization of 
PrPSc [31-341. These factors might be present in the 
PrPSC preparations at substoichiometric levels and may 
form part of the conversion mechanism. From the 
present study, we conclude that any such factor must co- 
purify with GdnHCl-resistant PrPSC aggregates and be 
resistant to PK. 
Reconciling the properties of the in vitro converting activity 
with those of the scrapie infectious agent 
Given the hypothesis that the activity that induces PrPsc 
formation is the infectious agent of scrapie, it is relevant to 
consider how the aggregated nature of the in vitro convert- 
ing activity compares to previous analyses of the size of 
the scrapie agent. Many studies have indicated that scrapie 
and Creutzfeldt-Jakob disease infectivity is associated with 
large sedimentable (> 40s) particles (for review, see 
[24,35]). But other analyses have indicated that much 
smaller sized particles can be infectious [36-381. For 
instance, scrapie-associated fibrils (SAF) or prion rods are 
not visible by electron microscopy in all infectious prepa- 
rations (e.g., liposome preparations) [36,39]. It is possible, 
however, that the low concentrations of small PrP aggre- 
gates required to nucleate polymerization might escape 
detection, especially in liposomes. Furthermore, the 
increased infectivity of a liposome-PrPsc suspension rela- 
tive to a sample containing the same amount of PrP in the 
form of amyloid fibrils [39] is consistent with the nucle- 
ation model in which smaller PrP aggregates would have a 
higher converting activity per PrP molecule. 
It must be emphasized that the nucleated polymerization 
model requires only that the seed be ordered, not that it 
have the morphological properties of an amyloid fibril. 
In fact, only PrP 27-30 is thought to have the character- 
istics of amyloid fibrils according to electron microscopy 
and Congo red staining.This might be due to a reorgani- 
zation of the structure into a fibril after proteolysis. It 
seems more likely, however, that the underlying poly- 
meric structure of protease-resistant PrPSC might be 
masked prior to proteolysis by the protease-sensitive 
amino-terminal domains of the PrPSC molecules, or by a 
less ordered binding of protease-sensitive PrP molecules 
to the surface of the polymer. The latter possibility is 
supported by the loss of a large proportion of the total 
PrP content in our PrPSC preparation after PK treatment 
(Fig 5).These PK-sensitive PrP molecules seem to be the 
same as those that are effectively solubilized away from 
the converting activity by 2.5-3M GdnHCl, since no 
solubilization of PrP was observed after PK treatment of 
PrPsc (Figs. 6,8). 
The sensitivity of the scrapie agent to inactivation by 
ionizing radiation is consistent with the agent being a 
PrP dimer of -55 kDa [37]. It is also consistent with the 
agent being substantially larger, however. Many 
oligomeric enzymes have produced monomeric target 
sizes, indicating that energy transfer between subunits 
does not occur and that the activity of each subunit can 
be independent of the activity of its neighbors in the 
oligomer [40-421. Similarly, if the scrapie agent is an 
aggregate of PrP, the interpretation of the radiation target 
size data will be complicated by the fact that a multi- 
merit PrP seed may be resistant to radiation damage of 
subunits that are not part of the growth face. The 
observed target size of 55 kDa may reflect a growth face 
defined by two PrP molecules within the context of a 
larger polymer. 
Significance 
The scrapie infectious agent may consist solely of 
a structural isomer of a normal cellular protein 
(prion protein, PrP). The molecular mechanism of 
scrapie infection remains a mystery, however, 
largely due to the difficulties associated with 
Scrapie-protein nucleation Caughey et al. 815 
designing unambiguous in viuo experiments. We 
have developed an in vitro model, which has 
several key properties that appear related to 
scrapie infection. This paper reports the initial 
characterization of the scrapie-brain-derived 
species (‘converting activity’) which is responsible 
for in vitro conversion of the cellular prion protein 
(PrPc) into a form which is biochemically indis- 
tinguishable from the scrapie-specific form, 
PrPsc. The converting activity required a threshold 
concentration of PrPsc, but was separated from 
soluble PrP by ultrafiltration and centrifugation. 
Sedimentation analysis demonstrated that the 
converting activity was associated with high mol- 
ecular weight aggregates of PrP. These data are 
consistent with a mechanism of conversion that 
resembles a crystallization process in that it is 
rate-limited by nucleus formation and accelerated 
by seeding. The nucleation mechanism is known 
to operate in the assembly of cytoskeletal compo- 
nents such as microtubules and pathological 
assemblies such as sickle cell fibrils and amyloid 
fibrils. Future experiments will be aimed at deter- 
mining whether this mechanism is operative in 
vivo. If that can be demonstrated, it may have 
implications for the et:iology and treatment of the 
transmissible spongifotm encephalopathies. 
Materials and methods 
PrpSc 
PrPsc was purified from the brains of hamsters infected with the 
263K strain of scrapie as described [17,25] and was sonicated 
into 0.5-l% sulfobetaine 3-14 in phosphate buffered saline 
(PBS; 2OmM sodium phosphate and 13OmM NaCl, pH 7.4) 
and stored at -20 “C prior to use. 
In some experiments, PrPSc was treated with PK prior to frac- 
tionation as follows. PrPSC at a concentration of 200 I*g ml-l in 
10% (w/v) NaCl, 1% sulfobetaine 3-14 in TEND (1OmM 
Tris-HCl, pH 8.3, 1 mM EDTA, 1 mM dithiothreitol (DTT) 
and 130 mM NaCl) was treated with 25 pg ml-’ PK for 1 h at 
37 “C.The reaction was stopped by adding aprotinin, leupeptin, 
and Pefabloc to 1.5 p,M, 10 PM, and 1 mM, respectively. The 
PrPSC was centrifuged for 15min at 12,000g at 4°C and the 
supernatant removed. The pellet was sonicated into 0.1% 
sarkosyl, 0.01 FM aprotinin and 1 p,M leupeptin, and the cen- 
trifugation repeated. The resultant pellet was sonicated into 
1% sulfobetaine 3-14 and F’BS and stored at -20 “C until use. 
35S-PrF 
The recombinant hamster PrPc used in this study was 
designed to contain all but the carboxy-terminal residue 
(Ser231) of the mature hamster PrPc. This protein will there- 
fore lack the glycophosphatidyl inositol (GPI) anchor [17], 
which is normally attached to Ser231 [43]. We have found this 
construct to be the one most efficiently labeled and converted 
to protease-resistant forms with hamster PrPSC in the cell-free 
conversion reaction. This construct was made by converting 
codon 231 to a stop codon in the hamster PrP gene [17], elim- 
inating the codons encoding Ser231 and the carboxy-terminal 
GPI signal sequence (residues 232-254) that is removed during 
normal biosynthesis [43). ‘This gene was cloned into a pSFF 
retroviral expression vector and expressed in mouse fibroblast 
cells by standard techniques [44]. 
A subclone of these fibroblasts was preincubated in methio- 
nine and cysteine-deficient minimal Eagle’s medium (MEM, 
supplemented with 1% dialyzed fetal bovine serum) for 1 h 
and incubated with the label (-1 mCi 35S methionine/cys- 
teine (Expre35S35S label, New England Nuclear) per 25-cm2 
flask of 60-80% confluent cells) for 90-120 min in this same 
medium. The cells were then washed and lysed in ice-cold 
lysing buffer (LB) containing 0.5% Triton X-100 and 0.5% 
sodium deoxycholate (1 ml per 25-cm2 flask).The lysates were 
cleared by centrifugation for 5 min at 1OOOg at 4”C, and the 
proteins precipitated with four volumes of methanol at -20 “C 
for 2 1 h. The precipitated proteins were resuspended by 
cuphorn sonication into DLPC buffer (0.05 M Tris-HCl, pH 
8.2, 0.15M NaCl, 2% (w/v) N-lauryl sarcosine, 0.4% (w/v) 
L-o-lecithin (from egg yolk)) [9]. The quantity of DLPC 
buffer used was 1 ml per 25-cm2 flask equivalent of cell pro- 
teins. Hamster PrP-specific monoclonal antibody 3F4 [45] was 
incubated with the suspension (2.5 l_tl ascites ml-’ DLPC) 
overnight at 4°C and antibody-antigen complexes were 
collected by binding to protein A Sepharose beads (10~1 of 
10% w/v suspension per p.1 of antibody). After washing the 
beads with DLPC buffer and then 1% N-laurylsarcosine, 
500 mM NaCl, 50 mM Tris-HCl, pH 7.0 at 4 “C, the residual 
liquid was drawn off the bead pellet with a Hamilton syringe 
and the PrP was eluted in 25 cl.1 of 3 M GdnHCl per 5 mg dry 
weight equivalent of beads. The beads were agitated in the 
eluant for 15 min at 37”CThe eluate was drawn off the beads, 
and the elution step repeated with fresh eluant. The eluates 
were stored on ice up to several weeks prior to use with no 
detectable degradation of PrPC. 
Cell-free conversion reaction 
Aliquots (2 p,l) of samples to be assayed for converting activity 
were mixed with 2 p,l of 35S PrPc (60000 counts per minute 
(cpm)) in 3M GdnHCl (estimated by semi-quantitative 
immunoblotting to be -5-10 ng total PrPC per 60 000 cpm of 
35S PrPC).This mixture was diluted with 12 l_tl of 2mM cetyl 
pyridinium chloride, 5OmM sodium citrate-HCl, pH 6.4 
(CPC-Cit) at 20 “C and incubated at 37 “C for 2-45 h. The 
mixture was diluted further with 64 p,l of 130mM NaCl, 
50 mM Tris-HCl, pH 7.4 (at 20°C) (TN).Then 2 p,l of 1 mg ml-l 
PK was added to give a final concentration of 25 p,g ml-‘.This 
mixture was incubated at 37°C for 1 h. The PK was then 
inhibited by adding 24 p.g Pefabloc (Boehringer-Mannheim) 
and 10 Fg of thyroglobulin (carrier protein). Methanol (four 
volumes at -20°C) was added to precipitate the remaining 
proteins. The precipitate was collected by centrifugation and 
subjected to SDS-PAGE on 14% acrylamide Novex precast 
gels. Radioactive proteins were detected in the gels by fluoro- 
graphy with Entensifj (DuPont) or with a Phosphorimager 
(Molecular Dynamics). The Phosphorimager was used to 
quantify PK-resistant 35S-labelled bands and to compare their 
radioactivity with that of the of 35S PrPc precursor bands. 
Centrifugation of PrPsc 
For the simple centrifugation of GdnHCl-treated PrPSC (as in 
Fig. 3), 50 ~1 of PrPsc, pretreated in 3M GdnHCl at 1 mg ml-’ 
for 5 h at 37 “C, was centrifuged at 70 000 rpm for 50 min at 
20°C in a Beckman TL1OO.l rotor. The supernatant was 
collected and the pellet was resuspended by cuphorn sonica- 
tion into 50 ~1 of fresh 3 M GdnHCl. Aliquots of each fraction 
were assayed for converting activity in the cell-free conversion 
816 Chemistry & Biology 1995, Vol 2 No 12 
reaction described above, and for total PrP content by 
immunoblotting as described below. 
Sedimentation velocity gradients were performed by layering 
20 p,l of a given PrPSC preparation (preincubated at 37 “C for 
2-18 h in 2.5M GdnHCl) over 40 ~1 of a solution with identi- 
cal GdnHCl concentration and 5 % (w/v) sucrose in a Beckman 
7 x 20 mm polycarbonate centrifuge tube. The tubes were spun 
to give the designated maximum g-force for 30 min at 20°C in 
a Beckman TLS 55 swinging bucket rotor using the slowest 
acceleration and deceleration settingsThe gradients were fiat- 
tionated as shown in Figure 4 and the pellet was sonicated into 
an additional 20 ~_tl of solution. Equal aliquots of the fractions 
were assayed for converting activity and for total PrP content by 
immunoblotting. Molecular weight standard proteins were dis- 
solved in 2.5M GdnHCl at -1 mg ml-’ and fractionated on 
gradients exactly as was PrPsc. The concentrations of the mole- 
cular weight standards in the fractions were determined by 
SDS-PAGE with silver staining, except in the cases of thyro- 
globulin and blue dextran. These proteins were too large to 
enter the SDS-PAGE gels; they were run on separate gradients 
and their concentrations in the fractions were determined by 
absorbance at 280 nm and 625 nm, respectively. 
Estimation of sedimentation coefficients 
The sedimentation coefficient (s, in Svedberg units) of parti- 
cles expected to be 90% cleared from the sedimentation 
velocity gradient sample zones within the time of centrifuga- 
tion (t in h) was estimated using the following equation 
(Beckman centrifuge manual): 
S ohs = k/t 
where k is the clearing factor for the sample zone given by 
k=253303 In (r,,/r,n)/(RPM/1000)2 
where rmaX and rti, are the maximum and minimum radii, 
respectively, of the sample zone within the spinning rotor and 
RPM is the revolutions per minute of the rotor. 
Estimates of the szO w values (s at 20°C in water) for the parti- 
cles were obtained ‘from s obs using equation (2) of Prusiner, et 
al. [46] to correct for the difference in density between 2.5M 
GdnHCl and water. No correction for a difference in viscosity 
was made. 
Ultrafiltration of PrPsC 
Millipore Ultrafree-MC polysulfone membrane 100 000 and 
300 000 NMWL filter units were used according to the manu- 
facturer’s instructions. PrPSC to be Sltered was first incubated in 
3 M GdnHCl at 37 “C at 1 mg ml-’ for 2-5 h. 50 ~1 of the 
PrPsc solution was loaded onto the filter and then centrifuged 
at l-2000 rpm until about half of the solution had been fil- 
tered. The retentate fractions were then diluted back to 50 p,l 
with 3 M GdnHCl (the filtrates were left neat) and 2 I.L~ of each 
was immediately added to a conversion reaction to assess con- 
verting activity. Equivalent parts of each fraction were also 
diluted and immunoblotted to determine the total PrP content. 
After an initial protease treatment, PK-treated PrPSC was filtered 
and assayed identically to non-protease-treated PrPsc. 
lmmunoblotting 
SDS-PAGE was performed using 20 % acrylamide PhastSystem 
gels (Pharmacia) (Figs. 3b, 7b) or Novex 14% acrylamide precast 
gels (all other figures). Gels were immunoblotted onto a PVDF 
Immobilon-P (M&pore) membrane using the PhastSystem 
blotter or a M&blot-SDE transfer system (Millipore). The 
membranes were blocked using 5 % nonfat dry milk in 0.05 % 
Tween 20,150mM NaCl, 1OmM Tris-HCl, pH 8.0 (TBST) and 
incubated with a polyclonal rabbit antibody to a synthetic 
peptide corresponding to hamster PrP residues 9(r104 [47] 
(1:2000 inTBST) at room temperature for 1 h. After washing, an 
anti-rabbit immunoglobulin, horseradish peroxidase-linked anti- 
body (Amersham) was incubated with the membranes for 
30 min.The membranes were then washed and developed with 
ECL chemiluminescence detection kit (Amersham). 
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